Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of alirocumab intensification on vascular and lipid parameters in routine care
2018-000981-12Phase 4Terminated
- Sponsor
- Medical University of Graz
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alirocumab in hypercholesterolemia, sponsored by Medical University of Graz. Primary endpoint: Effects of alirocumab intensification on vascular, inflammatory, and lipid parameters. Started Mar 2018; status: terminated.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2018-000981-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000981-12.